Cargando…
High doses of tigecycline are associated with satisfactory plasmatic and pulmonary concentrations for the treatment of severe infections due to fully susceptible bacteria: do we need even higher doses in patients under CRRT?
Autores principales: | Honore, Patrick M., Barreto Gutierrez, Leonel, Kugener, Luc, Redant, Sebastien, Attou, Rachid, Gallerani, Andrea, De Bels, David |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7560687/ https://www.ncbi.nlm.nih.gov/pubmed/33052490 http://dx.doi.org/10.1186/s13613-020-00758-5 |
Ejemplares similares
-
Hepcidin is described as the master regulator of iron: could its removal by CRRT lead to iron dysmetabolism in the critically ill?
por: Honore, Patrick M., et al.
Publicado: (2020) -
No dose adjustment of tigecycline is necessary during continuous renal replacement therapy: we are not sure
por: Honore, Patrick M., et al.
Publicado: (2020) -
500 mg as bolus followed by an extended infusion of 1500 mg of meropenem every 8 h failed to achieve in one-third of the patients an optimal PK/PD against non-resistant strains of these organisms: is CRRT responsible for this situation?
por: Honore, Patrick M., et al.
Publicado: (2020) -
Comparison between meropenem and ceftolozane/tazobactam: possible influence of CRRT
por: Honore, Patrick M., et al.
Publicado: (2022) -
Success rate of naso-jejunal tube placement influenced by CRRT: possible removal of metoclopramide
por: Honore, Patrick M., et al.
Publicado: (2021)